Home › Funds › Casdin Capital › NTLA
Casdin Capital position in NTLA
INTELLIA THERAPEUTICS INC · Health Care
Casdin Capital reported holding 355,000 shares of NTLA (INTELLIA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$6.0M, representing 0.30% of its reported portfolio and ranking #31 among its reported holdings. Casdin Capital has disclosed NTLA holdings in 13 of the last 16 reported quarters, going back to Q3 2022.
Last updated: 2026-10-05 · Source: SEC EDGAR Form 13F-HR
How Casdin Capital's NTLA position evolved
Casdin Capital first disclosed a stake in NTLA in Q3 2022 at 295,000 shares (US$16.5M). The position peaked in Q2 2023 at 1,275,000 shares, worth US$52.0M. Across 13 filings, Casdin Capital increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 355,000 shares valued at US$6.0M. Notable position changes include a 332% increase in Q1 2023 (shares rose 9% over the following quarter), a 97% trim in Q1 2024 (shares fell 19% over the following quarter), a 3900% increase in Q2 2024 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2022 | 295.00K | $16.51M | New |
| Q4 2022 | 295.00K | $10.29M | Hold |
| Q1 2023 | 1.27M | $47.52M | Add |
| Q2 2023 | 1.27M | $51.99M | Hold |
| Q3 2023 | 1.18M | $37.25M | Reduce |
| Q4 2023 | 1.45M | $44.21M | Add |
| Q1 2024 | 50.00K | $1.38M | Reduce |
| Q2 2024 | 2.00M | $44.76M | Add |
| Q3 2024 | 2.00M | $41.10M | Hold |
| Q4 2024 | 2.00M | $23.32M | Hold |
| Q1 2025 | 2.00M | $14.22M | Hold |
| Q1 2026 | 355.00K | $4.55M | New |
| Q2 2026 | 355.00K | $6.01M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NTLA and 13F data
NTLA (INTELLIA THERAPEUTICS INC) is a Health Care company. 39 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$285.5M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), REGENERON PHARMACEUTICALS, INC. (US$62.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NTLA
- ARK Invest 16.88M sh · $285.54M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 4.53M sh · $76.60M · Q2 2026
- REGENERON PHARMACEUTICALS, INC. 3.70M sh · $62.65M · Q2 2026
- Amova Asset Management Americas, Inc. 2.90M sh · $49.03M · Q2 2026
- Contrarius Group Holdings Ltd 1.96M sh · $33.08M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.50M sh · $25.38M · Q2 2026
- Ghisallo Capital Management LLC 1.20M sh · $20.30M · Q2 2026
- IQ EQ FUND MANAGEMENT (IRELAND) Ltd 777.95K sh · $13.16M · Q2 2026
More on Casdin Capital
FAQ
How long has Casdin Capital held NTLA?
Casdin Capital has disclosed NTLA holdings in 13 of the last 16 reported quarters, going back to Q3 2022.
What is Casdin Capital's current position in NTLA?
As of Q2 2026, Casdin Capital holds 355.00K shares of NTLA (INTELLIA THERAPEUTICS INC), valued at $6.01M, representing 0.30% of its reported portfolio and ranking #31.
Has Casdin Capital been buying or selling NTLA?
In the latest 13F filing (Q2 2026), Casdin Capital held unchanged its position in NTLA. The position peaked in Q2 2023 at 1.27M shares.
Which other funds hold NTLA?
Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., REGENERON PHARMACEUTICALS, INC., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.